Moffitt Notice of Blackbaud Data Incident. Learn More
Find a Doctor
Andreas Saltos, MD
Locations: Moffitt Cancer Center
Cancer Focus: Lung Cancer , Mesothelioma , Pancoast Tumor
Dr. Andreas Saltos earned his MD from the University of Maryland School of Medicine in Baltimore. He completed his Internal Medicine Residency at the University of Maryland Medical Center in Baltimore before moving to Tampa, where he completed a Hematology and Medical Oncology Fellowship at the University of South Florida Morsani College of Medicine and Moffitt Cancer Center. Dr. Saltos specializes in the treatment of thoracic malignancies, including all forms and stages of lung cancer. In his clinical practice he strives to match patients with the optimal treatments that are tailored to their specific cancer and individual needs. The ability to work with an incredible cancer team and apply the latest advances to treat patients in the clinic is what makes him excited to work at Moffitt. He also dedicates a significant portion of his effort to research. His focus is in clinical research aiming to find better treatments for lung cancers, including using new strategies for targeted therapy and immunotherapy. He is currently leading and developing clinical trials investigating novel drugs or treatment combinations which either target the specific genetic features of lung cancers or recruit the immune system to combat cancer. One of Dr. Saltos’ favorite speeches is by Jim Valvano at the 1993 ESPY awards, which he delivered during his battle with cancer. He provides an insightful perspective on life and brings attention to the mission of cancer research; he closes with “Cancer can take away all my physical abilities. It cannot touch my mind, it cannot touch my heart and it cannot touch my soul. And those three things are going to carry on forever.”
Education & Training
- Internal Medicine
- University of South Florida Moffitt Cancer Center - Hematology and Medical Oncology
- University of Maryland Medical Center -
- University of Maryland Medical Center - MD
CLINICAL TRIAL 19743
A Phase 2, Multicenter, Open-Label, 2-Cohort Study Of Trastuzumab Deruxtecan (DS-8201a), An Anti-HER2 Antibody Drug Conjugate (ADC), For HER2-Over-Expressing Or -Mutated, Unresectable And/Or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Intervention: Trastuzumab Deruxtecan ()
CLINICAL TRIAL 19948
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Intervention: Atezolizumab (Tecentriq); Cobimetinib ()
CLINICAL TRIAL 19656
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Intervention: Ceritinib (Zykadia); Taxotere (docetaxel); docetaxel ()
CLINICAL TRIAL 20178
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Intervention: AZD9291 (Osimertinib); IMC-1121B (Ramucirumab); Osimertinib (); Ramucirumab ()
CLINICAL TRIAL 20474
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
Intervention: XMT-1536 ()
CLINICAL TRIAL 20475
First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients with Solid Tumors
Intervention: Enapotamab Vedotin ()
- Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. A Prospective Single Arm Phase I/II Study: Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 Sep. Pubmedid: 33002543.
- Puri S, Saltos A, Perez B, Le X, Gray JE. Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep. 2020 Mar.22(4):31. Pubmedid: 32140986.
- Saltos A, Antonia S. Breaking the Impasse: Advances in Treatment of Small Cell Lung Cancer. Clin Chest Med. 2020 Jun.41(2):269-280. Pubmedid: 32402362.
- Saltos A, Shafique M, Chiappori A. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Front Oncol. 2020 Jul.10:1074. Pubmedid: 32766139. Pmcid: PMC7378389.
- Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
- Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, Gray JE. Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 2018 Nov.9(86):35666-35675. Pubmedid: 30479696. Pmcid: PMC6235019.
- Dagogo-Jack I, Saltos A, Shaw AT, Gray JE. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017 Nov.37:619-629. Pubmedid: 28561671.
- Pan J, Saltos A, Smith D, Johnson A, Vossoughi J. Comparison of Respiratory Resistance Measurements Made with an Airflow Perturbation Device with Those from Impulse Oscillometry. J Med Eng. 2016 Mar.2013:165782. Pubmedid: 27006908. Pmcid: PMC4782682.
- Simard JM, Koltz MT, Polifka AJ, Saltos A, Slawson RG, Kwok Y, Aldrich EF. Spetzler-Martin grade III arteriovenous malformations. Author reply. J Neurosurg. 2013 Sep.119(3):821-822. Pubmedid: 24137780.
- Koltz MT, Polifka AJ, Saltos A, Slawson RG, Kwok Y, Aldrich EF, Simard JM. Long-term outcome of Gamma Knife stereotactic radiosurgery for arteriovenous malformations graded by the Spetzler-Martin classification. J Neurosurg. 2013 Jan.118(1):74-83. Pubmedid: 23082882.
- Smith DC, Schreiber KM, Saltos A, Lichenstein SB, Lichenstein R. Ambulatory cell phone injuries in the United States: an emerging national concern. J Safety Res. 2013 Dec.47:19-23. Pubmedid: 24237866.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.